Cue Biopharma Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional · AccumulatedOther · Total | ||||||
|---|---|---|---|---|---|---|
| Shares | ParValue | Paid-inCapital | ComprehensiveIncome (Loss) | AccumulatedDeficit | Stockholders’Equity | |
| Balance, December 31, 2022 | 43,042,548 | $43 | $316,192 | $(96) | $(250,456) | $65,683 |
| Stock-based compensation | — | — | 1,998 | — | — | 1,998 |
| Exercise of stock options | 135,602 | — | 388 | — | — | 388 |
| Unrealized gain from available-for-sale securities | — | — | — | 57 | — | 57 |
| Net loss | — | — | — | — | (13,109) | (13,109) |
| Balance, March 31, 2023 | 43,178,150 | $43 | $318,578 | $(39) | $(263,565) | $55,017 |
| Balance, December 31, 2023 | 47,215,116 | $47 | $338,228 | $— | $(301,190) | $37,085 |
| Issuance of common stock from ATM offering, net of sales agent commission and fees | 1,428,200 | 1 | 3,353 | — | — | 3,354 |
| Stock-based compensation | — | — | 1,946 | — | — | 1,946 |
| Net loss | — | — | — | — | (12,347) | (12,347) |
| Balance, March 31, 2024 | 48,643,316 | $48 | $343,527 | $— | $(313,537) | $30,038 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.